The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure
Open accessAbstract
BACKGROUND: Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure or death from cardiovascular causes among patients with stable heart failure. However, the safety and efficacy of SGLT2 inhibitors when initiated soon after an episode of decompensated heart failure are unknown. METHODS: We performed a multicenter, double-blind trial in which patients with type 2 diabetes mellitus who were recently hospitalized for worsening heart failure were randomly assigned to receive sotagliflozin or placebo. The primary end point was the total number of deaths from cardiovascular causes and hospitalizations and urgent visits for heart failure (first and subsequent events). The trial ended early because of loss of funding from the sponsor. RESULTS: A total of 1222 patients underwent randomization (608 to the sotagliflozin group and 614 to the placebo group) and were followed for a median of 9.0 months; the first dose of sotagliflozin or placebo was administered before discharge in 48.8% and a median of 2 days after discharge in 51.2%. Among these patients, 600 primary end-point events occurred (245 in the sotagliflozin group and 355 in the placebo group). The rate (the number of events per 100 patient-years) of primary end-point events was lower in the sotagliflozin group than in the placebo group (51.0 vs. 76.3; hazard ratio, 0.67; 95% confidence interval [CI], 0.52 to 0.85; P<0.001). The rate of death from cardiovascular causes was 10.6 in the sotagliflozin group and 12.5 in the placebo group (hazard ratio, 0.84; 95% CI, 0.58 to 1.22); the rate of death from any cause was 13.5 in the sotagliflozin group and 16.3 in the placebo group (hazard ratio, 0.82; 95% CI, 0.59 to 1.14). Diarrhea was more common with sotagliflozin than with placebo (6.1% vs. 3.4%), as was severe hypoglycemia (1.5% vs. 0.3%). The percentage of patients with hypotension was similar in the sotagliflozin group and the placebo group (6.0% and 4.6%, respectively), as was the percentage with acute kidney injury (4.1% and 4.4%, respectively). The benefits of sotagliflozin were consistent in the prespecified subgroups of patients stratified according to the timing of the first dose. CONCLUSIONS: In patients with diabetes and recent worsening heart failure, sotagliflozin therapy, initiated before or shortly after discharge, resulted in a significantly lower total number of deaths from cardiovascular causes and hospitalizations and urgent visits for heart failure than placebo. (Funded by Sanofi and Lexicon Pharmaceuticals; SOLOIST-WHF ClinicalTrials.gov number, NCT03521934.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“A comprehensive meta-analysis of 6 major SGLT2i trials in individuals with T2D, comprising nearly 50,000 participants showed a 32% reduction in the risk of hospitalization for HF (HR, 0.68; 95% CI, 0.61–0.76), a 22% reduction in the composite of hypertensive HF and CV death (HR, 0.78; 95% CI, 0.73–0.84), and a 15% reduction in CV death (HR, 0.85; 95% CI, 0.78–0.93) with SGLT2is vs placebo.649”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [649]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“All of these benefits were consistent regardless of presence or absence of ASCVD.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [649]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A comprehensive meta-analysis of 6 major SGLT2i trials in individuals with T2D, comprising nearly 50,000 participants showed a 32% reduction in the risk of hospitalization for HF (HR, 0.68; 95% CI, 0.61–0.76), a 22% reduction in the composite of hypertensive HF and CV death (HR, 0.78; 95% CI, 0.73–0.84), and a 15% reduction in CV death (HR, 0.85; 95% CI, 0.78–0.93) with SGLT2is vs placebo.649”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [649]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Secondary analyses across several of these trials also showed that HF prevention benefits of SGLT2is are present regardless of baseline CV or antihyperglycemic therapies (including metformin) (Fig. 5).649”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [649]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A comprehensive meta-analysis of 6 major SGLT2i trials in individuals with T2D, comprising nearly 50,000 participants showed a 32% reduction in the risk of hospitalization for HF (HR, 0.68; 95% CI, 0.61–0.76), a 22% reduction in the composite of hypertensive HF and CV death (HR, 0.78; 95% CI, 0.73–0.84), and a 15% reduction in CV death (HR, 0.85; 95% CI, 0.78–0.93) with SGLT2is vs placebo.649”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [649]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, there was also a modest but significant 10% reduction in the risk of MACE (HR, 0.90; 95% CI, 0.85–0.95).649”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [649]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although there were low rates of ketoacidosis in the cardiovascular and heart failure outcomes trials evaluating SGLT inhibition, these studies excluded individuals with type 1 diabetes and/or recent history of diabetic ketoacidosis (309,312).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [309]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, the relatively small percentage of such individuals enrolled (only 21% of participants had ejection fraction >50%) and the early termination of the trial limited the ability to determine the effects of sotagliflozin in HFpEF specifically (309).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [309]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although there were low rates of ketoacidosis in the cardiovascular and heart failure outcomes trials evaluating SGLT inhibition, these studies excluded individuals with type 1 diabetes and/or recent history of diabetic ketoacidosis (296,298).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [296]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The studies that led to the approved indication for heart failure (HF) excluded individuals with type 1 diabetes or a history of DKA (82,83).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [82]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Sotagliflozin significantly reduced the risk of achieving the primary end point of CV death, HHF, or urgent visit for HF (51.0 vs 76.3 events per 100 patient-years; HR, 0.67 [95% CI 0.52-0.85]).”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [83]
The cited source says what the claim attributes to it.
In the citing paper
“There was no signi fi cant interaction by eGFR status for the primary outcome.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [103]
The cited source says what the claim attributes to it.
In the citing paper
“sotaglifl ozin did reduce the primary outcome by 33% (HR: 0.67; 95% CI: 0.52 -0.85).”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [103]
The cited source says what the claim attributes to it.
In the citing paper
“In the SOLOIST trial, sotagliflozin initiated during or shortly after hospitalization in people with diabetes also reduced the risk for the primary end point of deaths from cardiovascular causes and hospitalizations and urgent visits for heart failure (309).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [309]
The cited source says what the claim attributes to it.
In the citing paper
“ultimately no evidence of heterogeneity of treatment effect by ejection fraction was noted.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [309]
The cited source says what the claim attributes to it.
In the citing paper
“In the Effect of Sotagliflozin on Cardiovascular Events in Patients With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF) trial, sotagliflozin, a combined SGLT1/2 inhibitor, initiated during or shortly after hospitalization for heart failure in people with diabetes, also reduced the risk for the primary end point of deaths from cardiovascular causes and hospitalizations and urgent visits”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [296]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Sub-group analyses considering those co-prescribed MRA and SGLT2 inhibitors suggest their combined use does not modify safety findings from the key trials.150,189,[722][723][724][725][726]”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [189]
Experimental — accuracy not yet measuredIn the citing paper
“Canagliflozin, Dapagliflozin, Sotagliflozin significantly decrease the composed primary end-point, including cardiovascular mortality and other cardiovascular outcomes [10,11,12].”
From Neuroprotective effect of SGLT2 inhibitors. (2021) · cites this paper as [12]
In the citing paper
“Sotagliflozin reduced the risk of the primary composite outcome of CV death, HF hospitalization, and urgent visit for HF by 33%, with a consistent effect across the spectrum of baseline LVEF.However, the number of events in the HFpEF group was too small to draw any firm conclusion.189”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [189]
In the citing paper
“Sotagliflozin significantly reduced the RR of the composite primary outcome (CV death, HF hospitalization, or urgent visit for HF) by 33% compared with placebo (HR 0.67; 95% CI, 0.52-0.85).The treatment effect was consistent across the spectrum of LVEF.189”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [189]
In the citing paper
“However, the relatively small percentage of such patients enrolled (only 21% of participants had ejection fraction > 50%) and the early termination of the trial limited the ability to determine the effects of sotagli fl ozin in HFpEF speci fi cally.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [228]
In the citing paper
“No signi fi cant between-group differences were found in the rates of cardiovascular death or all-cause mortality.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [228]
In the citing paper
“At a median follow-up of 9 months, the rate of primary end point events (the total number of cardiovascular deaths and hospitalizations and urgent visits for heart failure) was lower in the sotaglifl ozin group than in the placebo group (51.0 vs. 76.3; HR 0.67 [95% CI 0.52 -0.85]; P < 0.001).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [228]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Self-citationDapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Self-citationCanagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189
Self-citationDapagliflozin in Patients with Chronic Kidney Disease
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024816 · Cited by 5,618
Cardiovascular and renal outcomes with empagliflozin in heart failure
Packer, M., Anker, S. D., Butler, J., Filippatos, G., Pocock, S. J., Carson, P., Januzzi, J., Verma, S., Tsutsui, H., Brueckmann, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022190 · Cited by 5,206
Self-citationSaxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470
Self-citationZelniker, T. A., Wiviott, S. D., Raz, I., Im, K., Goodrich, E. L., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Furtado, R. H. M., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32590-x · Cited by 2,845
Self-citationThe Robust Inference for the Cox Proportional Hazards Model
Lin, D. Y., & Wei, L. J. (1989) · Journal of the American Statistical Association · doi:10.1080/01621459.1989.10478874 · Cited by 2,695
Research works printed but not linked: 1
- Scirica BM, Braunwald E, Raz I, et al. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation 2015;132(15):e198-e198.26459088
Cited by
Sorted by citations
Items 701–800 of 1,000
A Stepwise Guide to the Diagnosis and Treatment of Heart Failure With Preserved Ejection Fraction
Vaishnav, J., & Sharma, K. (2021) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2021.12.013 · Cited by 15
Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor: In the heart of the problem
Vallianou, N. G., Christodoulatos, G. S., Kounatidis, D. C., & Dalamaga, Μ. (2021) · Metabolism Open · doi:10.1016/j.metop.2021.100089 · Cited by 15
Koufakis, T., Liberopoulos, E. N., & Kotsa, K. (2022) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-022-00527-8 · Cited by 13
Bánfi‐Bacsárdi, F., Muk, B., Pilecky, D., Duray, G. Z., Kiss, R. G., & Nyolczas, N. (2022) · Cardiology · doi:10.1159/000528505 · Cited by 13
Kim, I., Cho, H., Lim, S. K., Seok, S. H., & Lee, H. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-01002-3 · Cited by 13
Pozzi, A., Cirelli, C., Merlo, A., Rea, F., Scangiuzzi, C., Tavano, E., Iorio, A., Kristensen, S. L., Wong, C., Iacovoni, A., et al. (2023) · Heart Failure Reviews · doi:10.1007/s10741-023-10363-w · Cited by 13
Rationale and Design of the ESC Heart Failure III Registry – Implementation and Discovery
Lund, L. H., Crespo‐Leiro, M. G., Laroche, C., García‐Pinilla, J. M., Bennis, A., Vataman, E., Polovina, M. M., Radovanović, S., Apostolovic, S. R., Ašanin, M., et al. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.3087 · Cited by 13
Self-citationTaheri, S. (2023) · World Journal of Nephrology · doi:10.5527/wjn.v12.i5.182 · Cited by 13
Varshney, A. S., Calma, J., Kalwani, N. M., Hsiao, S., Sallam, K., Cao, F., Din, N., Schirmer, J., Bhatt, A. S., Ambrosy, A. P., et al. (2024) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2023.12.018 · Cited by 13
Proximal versus distal diuretics in congestive heart failure
Nardone, M., Sridhar, V. S., Yau, K., Odutayo, A., & Cherney, D. Z. I. (2024) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfae058 · Cited by 14
Use of Sodium–Glucose Cotransporter 2 Inhibitors in Hospitalized Patients
Ünlü, O., Bhatt, A. S., & Blood, A. J. (2024) · JACC Advances · doi:10.1016/j.jacadv.2024.101024 · Cited by 13
New Perspectives in Management of Cardiovascular Risk Among People With Diabetes
Gami, A., Blumenthal, R. S., McGuire, D. K., Sarkar, S., & Kohli, P. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.034053 · Cited by 13
Self-citationContemporary treatment options in heart failure with preserved ejection fraction
Peikert, A., & Solomon, S. D. (2024) · European Heart Journal - Cardiovascular Imaging · doi:10.1093/ehjci/jeae201 · Cited by 13
The Current State of Realistic Heart Models for Disease Modelling and Cardiotoxicity
Kistamás, K., Lamberto, F., Vaičiulevičiūtė, R., Leal, F., Muenthaisong, S., Marte, L., Subías-Beltrán, P., Alaburda, A., Arvanitis, D. N., Zana, M., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25179186 · Cited by 13
Shah, M. U., Roebuck, A., Srinivasan, B., Ward, J. K., Squires, P. E., Hills, C. E., & Lee, K. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1499681 · Cited by 15
Novel Antidiabetic Drugs and Risk of Venous Thromboembolism: A Literature Review
Chen, Q., Anijs, R. J. S., Verlaan, J. P. L., Scheres, L. J. J., Klok, F. A., & Cannegieter, S. C. (2025) · Seminars in Thrombosis and Hemostasis · doi:10.1055/a-2546-0353 · Cited by 13
SGLT-2 inhibitors: A step forward in the treatment of heart failure with reduced ejection fraction
Silva‐Cardoso, J., Andrade, A., Brito, D. A., Ferreira, J., Fonseca, C., Peres, M., Franco, F., & Moura, B. (2021) · Revista Portuguesa de Cardiologia · doi:10.1016/j.repc.2021.02.010 · Cited by 13
Li, W., Katamreddy, A., Kataria, R., Myerson, M. L., & Taub, C. C. (2021) · Drugs - Real World Outcomes · doi:10.1007/s40801-021-00277-0 · Cited by 13
Heart failure with preserved ejection fraction: a stepchild no more!
Braunwald, E. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab601 · Cited by 13
Barraclough, J., Patel, S., Yu, J., Neal, B. C., & Arnott, C. G. (2021) · Cells · doi:10.3390/cells10102699 · Cited by 13
The SGLT-2 Inhibitors in Personalized Therapy of Diabetes Mellitus Patients
Tilinca, M. C., Tiucă, R. A., Ţilea, I., & Varga, A. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11121249 · Cited by 15
Safety and effects of SGLT-2 inhibitor use among LVAD patients with type 2 diabetes mellitus
Cagliostro, M., Hundal, P., Ting, P., Patel, S. A., Sudarshan, S., Thomas, J., Morris, K. L., MANCINI, D. M., Moss, N., Lala, A., et al. (2022) · American Heart Journal Plus Cardiology Research and Practice · doi:10.1016/j.ahjo.2022.100154 · Cited by 13
Effect of sotagliflozin on ventricular arrhythmias in mice with myocardial infraction
Gong, Y., Kong, B., Shuai, W., Chen, T., Zhang, J., & Huang, H. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.175357 · Cited by 13
Jha, K. K., Adhikari, R., Tasdighi, E., Osuji, N., Rajan, T., & Blaha, M. J. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01066-y · Cited by 13
Chen, H., Yang, Y., Meng, R., & Liu, X. (2023) · ESC Heart Failure · doi:10.1002/ehf2.14297 · Cited by 13
Meta‐analysis of Association between Newer Glucose‐Lowering Drugs and Risk of Parkinson's Disease
Tang, H., Lu, Y., Okun, M. S., Donahoo, W. T., Ramirez‐Zamora, A., Wang, F., Huang, Y., Chen, W., Virnig, B. A., Bian, J., et al. (2023) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.13893 · Cited by 14
Advances in Clinical Cardiology 2020: A Summary of Key Clinical Trials
Kearney, A., Linden, K., Savage, P., & Menown, I. B. A. (2021) · Advances in Therapy · doi:10.1007/s12325-021-01711-z · Cited by 13
Gronda, E., Vanoli, E., Iacoviello, M., Urbinati, S., Caldarola, P., Colivicchi, F., & Gabrielli, D. (2022) · Heart Failure Reviews · doi:10.1007/s10741-021-10211-9 · Cited by 13
Tang, H., Kimmel, S. E., Smith, S. M., Cusi, K. J., Shi, W., Gurka, M. J., Winterstein, A. G., & Guo, J. S. (2022) · Diabetes Care · doi:10.2337/dc21-1722 · Cited by 13
Report from the CVOT Summit 2020: new cardiovascular and renal outcomes
Schnell, O., Cos, X., Cosentino, F., Forst, T. M., Giorgino, F., Heersprink, H. J. L., Kosiborod, M., Wanner, C., & Standl, E. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01254-1 · Cited by 13
Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H., Müller-Wieland, D., Nauck, M. A., Wiesner, T., & Siegel, E. (2022) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1624-3449 · Cited by 12
Virani, S., Zieroth, S. R., Aleksova, N., Anderson, K., Clarke, B., Ducharme, A., Ezekowitz, J. A., Foroutan, F., Giannetti, N., Jain, R., et al. (2025) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2025.07.027 · Cited by 15
RetractedBodea, O.-M., Serban, S., Craciun, M.-L., Mateescu, D.-M., Florescu, E., Mureșan, C.-O., Cotet, I.-G., Badalica-Petrescu, M., Munteanu, A. M., Velimirovici, D. E., et al. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15010378 · Cited by 12
Diuretics and Clinical Management of Congestion in Heart Failure: A Review
Piardi, D. S., Butzke, M., & Neto, L. B. D. S. (2021) · ABC Heart Failure & Cardiomyopathy · doi:10.36660/abchf.20210009 · Cited by 12
Tian, L., Ai, S., Zheng, H., Yang, H., Zhou, M., Tang, J., Liu, W., Zhao, W., & Wang, Y. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.986186 · Cited by 12
Cardio‐renal‐metabolic disease in primary care setting
Ibrahim, M. A., Ba-Essa, E. M., Baker, J. C., Cahn, A., Ceriello, A., Cosentino, F., Davies, M. J., Eckel, R. H., Gaal, L. V., Gæde, P., et al. (2023) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3755 · Cited by 13
Pagnesi, M., Vilamajó, O. A. G., Meiriño, A., Dumont, C. A., Mebazaa, A., Davison, B. A., Adamo, M., Arrigo, M., Barros, M., Biegus, J., et al. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3174 · Cited by 12
Self-citationBonacchi, G., Rossi, V. A., Garofalo, M., Mollace, R., Uccello, G., Pieragnoli, P., Checchi, L., Perrotta, L., Voltolini, L., Ricciardi, G., et al. (2024) · Biomedicines · doi:10.3390/biomedicines12050981 · Cited by 14
Wu, C., Shah, B. R., Sharma, A., Sheng, Y., Liu, P. P., Kopp, A., Saskin, R., Edwards, J. D., & Swardfager, W. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3464 · Cited by 12
Hamid, A. K., Tayem, A. A., Al-Aish, S. T., Sakini, A. S. A., Hadi, D. D., & Al-Aish, R. T. (2024) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/17539447241289067 · Cited by 12
New and future heart failure drugs
Haghighat, L., DeJong, C., & Teerlink, J. R. (2024) · Nature Cardiovascular Research · doi:10.1038/s44161-024-00576-z · Cited by 14
Theodorakis, N., Nikolaou, M., & Krentz, A. J. (2025) · Biomolecules · doi:10.3390/biom15030373 · Cited by 12
Transition to Advanced Heart Failure: From Identification to Improving Prognosis
Tepetes, N.-I., Kourek, C., Papamichail, A., Xanthopoulos, A. V., Kostakou, P. M., PARASKEVAIDIS, I. A., & Briasoulis, Α. (2025) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd12030104 · Cited by 13
Management of Atrial Fibrillation in Elderly Patients: A Whole New Ballgame?
Parrini, I., Lucà, F., Rao, C. M., Ceravolo, R., Gelsomino, S., Ammendolea, C., Pezzi, L., Ingianni, N., Sindaco, D. D., Murrone, A., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14072328 · Cited by 12
Kadowaki, T., Yamamoto, F., Taneda, Y., Naito, Y., Clark, D., Lund, S. S., Okamura, T., & Kaku, K. (2021) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2021.1898585 · Cited by 12
Qiu, M., Ding, L., & Zhou, H. (2021) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-021-00484-8 · Cited by 12
Sodium-glucose cotransporter type 2 inhibitors: successful running after two hares
Перепеч, Н. Б., & Mikhailova, I. E. (2021) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2021-4534 · Cited by 12
Diabetic proximal tubulopathy: Can we mimic the disease for in vitro screening of SGLT inhibitors?
Faria, J., Gerritsen, K. G. F., Nguyen, T. Q., Mihaila, S. M., & Masereeuw, R. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174378 · Cited by 12
Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure
Shah, K., & Fang, J. C. (2021) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-052120-014725 · Cited by 12
Passantino, A., Rizzo, C., Scrutinio, D., & Palazzuoli, A. (2021) · Heart Failure Reviews · doi:10.1007/s10741-021-10186-7 · Cited by 12
Can SGLT2 inhibitors answer unmet therapeutic needs in chronic kidney disease?
Nicola, L. D., Cozzolino, M. G., Genovesi, S., Gesualdo, L., Grandaliano, G., & Pontremoli, R. (2022) · Journal of Nephrology · doi:10.1007/s40620-022-01336-7 · Cited by 14
Cvijić, M., Rib, Y., Danojevic, S., Radulescu, C.-I., Nazghaidze, N., & Vardas, P. E. (2022) · Heart Failure Reviews · doi:10.1007/s10741-022-10267-1 · Cited by 13
Modern Approaches for the Treatment of Heart Failure: Recent Advances and Future Perspectives
Popa, I. P., Haba, M. Ș. C., Maranducă, M. A., Tănase, D. M., Șerban, D. N., Șerban, L., Iliescu, R., & Tudorancea, I. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091964 · Cited by 13
Zhou, F., Du, N., Zhou, L., Wang, C., Ren, H., & Sun, Q. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.968478 · Cited by 12
SGLT2 Inhibitors in Heart Failure
Dixit, N. M., Ziaeian, B., & Fonarow, G. C. (2022) · Heart Failure Clinics · doi:10.1016/j.hfc.2022.03.003 · Cited by 12
The Benefit of Sodium-Glucose Co-Transporter Inhibition in Heart Failure: The Role of the Kidney
Gronda, E., Vanoli, E., Iacoviello, M., Caldarola, P., Gabrielli, D., & Tavazzi, L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911987 · Cited by 12
Recency of Heart Failure Hospitalization, Outcomes, and the Effect of Empagliflozin
Ferreira, J. P., Zannad, F. M., Butler, J., Filippatos, G. S., Pocock, S., Iwata, T., Sumin, M., Zeller, C., Januzzi, J. L., Anker, S. D., et al. (2023) · JACC Heart Failure · doi:10.1016/j.jchf.2023.01.018 · Cited by 12
Escobar, C., Palacios, B., Gonzalez, V., Gutiérrez, M., Duong, M., Chen, H., Justo, N., Cid-Ruzafa, J., Hernández, I., Hunt, P. R., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12062410 · Cited by 12
Time to Benefit With Sotagliflozin in Patients With Worsening Heart Failure
Verma, S., Bhatt, D. L., Dhingra, N. K., Steg, P. G., Szarek, M. J., Davies, M., Metra, M., Lund, L. H., & Pitt, B. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.02.022 · Cited by 12
Self-citationPractical Guidance for the Use of SGLT2 Inhibitors in Heart Failure
Cavallari, I., Crispino, S. P., Segreti, A., Ussia, G. P., & Grigioni, F. (2023) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-023-00601-9 · Cited by 13
Exploring SGLT-2 Inhibitors: Benefits beyond the Glucose-Lowering Effect—What Is New in 2023?
Young, C. F., Farnoudi, N., Chen, J., & Shubrook, J. H. (2023) · Endocrines · doi:10.3390/endocrines4030045 · Cited by 14
Gliflozins for the prevention of stroke in diabetes and cardiorenal diseases
Zhao, L., Huang, J.-N., Qiu, M., Ding, L., Zhan, Z., & Ning, J. (2021) · Medicine · doi:10.1097/md.0000000000027362 · Cited by 12
The year in cardiovascular medicine 2021: diabetes and metabolic disorders
Cosentino, F., Bhatt, D. L., Marx, N., & Verma, S. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab876 · Cited by 12
Self-citationNorre, T., Grimm, D. G., & Simonsen, U. (2022) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13714 · Cited by 13
Koufakis, T., Doumas, M. N., Bargiota, Α., Kotsa, K., & Maltese, G. (2023) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2023.2247977 · Cited by 12
Wang, H., Gao, C., Guignard‐Duff, M., Cole, C., Hall, C., Baruah, R., Das, S., Gao, H., Mamza, J. B., Lang, C. C., et al. (2025) · Heart · doi:10.1136/heartjnl-2024-324160 · Cited by 13
Haider, S. H., Irfan, A., Sheikh, S. M., Larik, M. O., Raza, A., & Khabir, Y. (2025) · Clinical Medicine Insights Cardiology · doi:10.1177/11795468251347777 · Cited by 12
Acute Cardiorenal Syndrome: An Update
Sohal, S., Uppal, D., Mathai, S. V., Wats, K., & Uppal, N. N. (2023) · Cardiology in Review · doi:10.1097/crd.0000000000000532 · Cited by 11
Li, J., Zhu, C., Liang, J., Hu, J., Liu, H., Wang, Z., Guan, R., Chow, J., Yan, S., Li, L., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1303694 · Cited by 11
Nag, S., Mitra, O., Maturi, B., Kaur, S. P., Saini, A., Nama, M., Roy, S., Samanta, S., Chacko, L., Dutta, R., et al. (2024) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2024.100927 · Cited by 12
Radakrishnan, A., Agrawal, S., Singh, N., Barbieri, A., Shaw, L. J., Gulati, M., & Lala, A. (2025) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2025.100928 · Cited by 12
Chen, J.-J., Hsu, C., Hung, C., Liang, C., Su, K., Carvalho, A. F., Stubbs, B., Chen, Y.-W., Chen, T., Lei, W., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18050735 · Cited by 13
Yamani, H. Z., Hassan, Y. H., Magdy, N., Ghany, M. F. A., & Gomaa, M. M. (2025) · Microchimica Acta · doi:10.1007/s00604-025-07235-5 · Cited by 11
Starr, J. A., Pinner, N. A., Lisenby, K. M., & Osmonson, A. J. (2021) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2527 · Cited by 12
Kolben, Y., Kessler, A., Puris, G., Nachman, D., Alvarez, P. A., Briasoulis, Α., & Asleh, R. (2022) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2301016 · Cited by 11
Diabetes mellitus and heart failure: an update on pathophysiology and therapy
Potere, N., BUONO, M. G. D., Vecchié, A., Porreca, E., ABBATE, A., DENTALI, F., & Bonaventura, A. (2022) · Minerva Cardiology and Angiology · doi:10.23736/s2724-5683.22.05967-1 · Cited by 11
Fukuta, H., Hagiwara, H., & Kamiya, T. (2022) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2022.101103 · Cited by 12
Harikrishnan, S., Oomman, A., Jadhav, U., Raghuraman, B., Mohanan, P. P., TIWASKAR, M. H., Wander, G., & Chopra, V. (2022) · Journal of the Association of Physicians of India · doi:10.5005/japi-11001-0077 · Cited by 11
Elkammash, A., Tam, S. S. C., Yogarajah, G., & You, J. (2023) · Cureus · doi:10.7759/cureus.35030 · Cited by 12
Lee, M. M. Y., & Sattar, N. A. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15085 · Cited by 11
Park, S. M., Lee, S. Y., Jung, M., Youn, J., Kim, D., Cho, J. Y., Cho, D., Hyun, J., Cho, H., Park, S., et al. (2023) · Korean Circulation Journal · doi:10.4070/kcj.2023.0114 · Cited by 11
Wu, M., Ying, W., Chen, W., Kaizu, X., Song, M., & Lin, L. (2023) · Heart Failure Reviews · doi:10.1007/s10741-023-10338-x · Cited by 13
Heart Failure with Preserved Ejection Fraction: How to Deal with This Chameleon
Lucà, F., Oliva, F. G., Abrignani, M. G., Fusco, S. A. D., Gori, M., Giubilato, S., Ceravolo, R., Temporelli, P. L., Cornara, S., Rao, C. M., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13051375 · Cited by 14
SGLT-2 inhibitors in heart failure and chronic kidney disease: A review for internists
Jaswaney, R., Sokoloff, S., Rakita, V., & Rubin, D. J. (2024) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.91a.23093 · Cited by 12
SGLT-2 Inhibitors in Heart Failure: Guide for Prescribing and Future Perspectives
Garla, V. V., Butler, J., & Lien, L. F. (2021) · Current Cardiology Reports · doi:10.1007/s11886-021-01486-3 · Cited by 11
Benefits of sodium glucose cotransporter 2 inhibitors across the spectrum of cardiovascular diseases
Gulsin, G. S., Graham-Brown, M. P. M., Squire, I. B., Davies, M. J., & McCann, G. P. (2021) · Heart · doi:10.1136/heartjnl-2021-319185 · Cited by 12
Sotagliflozin and decompensated heart failure: results of the SOLOIST-WHF trial
Shah, S. R., Ali, A., & Ikram, S. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1908123 · Cited by 11
Canagliflozin and myocardial oxidative stress: SGLT1 inhibition takes centre stage
Schiattarella, G. G., & Bode, D. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab519 · Cited by 11
Proposed New Conceptualization for Definition of Decompensated HF
Bozkurt, B. (2023) · JACC Heart Failure · doi:10.1016/j.jchf.2023.02.001 · Cited by 11
Rethinking diuretics for congestion in acute heart failure: insight from the STRONG-HF trial
Caillard, A., Čerlinskaitė‐Bajorė, K., & Mebazaa, A. (2024) · European Journal of Emergency Medicine · doi:10.1097/mej.0000000000001151 · Cited by 11
Kani, R., Miyamoto, Y., Saito, T., Watanabe, A., Matsubara, K., Ejiri, K., Iwagami, M., Slipczuk, L., Hosseini, K., Fujisaki, T., et al. (2025) · International Journal of Cardiology · doi:10.1016/j.ijcard.2025.133079 · Cited by 10
Three new categories of hypoglycaemic agents and various cardiovascular diseases: A meta‐analysis
Liao, X., Li, W., Peng, Z., Yu, H., & Tan, J. (2021) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13588 · Cited by 10
Use of Sodium Glucose Co-Transporter 2 Inhibitors in Acute Heart Failure: A Practical Guidance
Ferreira, J. P., Pimenta, J. M., Moura, B., Aguíar, C., & Franco, F. (2022) · ESC Heart Failure · doi:10.1002/ehf2.14090 · Cited by 10
Wahinya, M., & Khan, Z. U. (2023) · Cureus · doi:10.7759/cureus.37388 · Cited by 10
Matsukawa, R., Okahara, A., Tokutome, M., Itonaga, J., Hara, A., Kisanuki, H., Sada, M., Okabe, K., Kawai, S., Matsuura, H., et al. (2023) · Circulation Reports · doi:10.1253/circrep.cr-22-0118 · Cited by 10
Pironti, G. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1228789 · Cited by 11
Management of Heart Failure in Hospitalized Patients
Kittleson, M. M. (2023) · Annals of Internal Medicine · doi:10.7326/aitc202312190 · Cited by 10
Theodorakopoulou, M. P., Alexandrou, M. E., Tsitouridis, A., Kamperidis, V., Pella, E., Xanthopoulos, A. V., Ziakas, A., Triposkiadis, F. K., Vassilikos, V. P., Papagianni, A. A., et al. (2024) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvae003 · Cited by 11
Sotagliflozin attenuates liver-associated disorders in cystic fibrosis rabbits
Liang, X., Hou, X., Bouhamdan, M., Sun, Y., Song, Z., Rajagopalan, C., Jiang, H., Wei, H., Song, J., Yang, D., et al. (2024) · JCI Insight · doi:10.1172/jci.insight.165826 · Cited by 11
Wang, Q., Yu, J., Deng, W., Liu, C., Yang, J., Li, Y., Cai, G., Chen, X., & Dong, Z. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1372421 · Cited by 10
Metadata
- Authors
- Bhatt, D. L., Szarek, M., Steg, P. G., Cannon, C. P., Leiter, L. A., McGuire, D. K., Lewis, J. B., Riddle, M. C., Voors, A. A., Metra, M., Lund, L. H., Komajda, M., Testani, J. M., Wilcox, C. S., Ponikowski, P., Lopes, R. D., Verma, S., Lapuerta, P., & Pitt, B.
- Affiliations
- Brigham and Women's Hospital (US)
- From Brigham and Women’s Hospital Heart and Vascular Center and Harvard Medical School, Boston (D.L.B., C.P.C.); Colorado Prevention Center Clinical Research and Department of Medicine, Division of Cardiovascular Medicine, University of Colorado Anschutz Medical Campus, Aurora (M.S.); State University of New York Downstate School of Public Health, Brooklyn (M.S.); Université de Paris, French Alliance for Cardiovascular Trials, Assistance Publique–Hôpitaux de Paris, Hôpital Bichat, INSERM Unité 1148 ...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-01-14
- Volume
- 384
- Issue
- 2
- Pages
- 117-128
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3100542962
- Semantic Scholar
- a022df46be992be653dc8f2439f324470b7eb318
- Cited by
- 1,868
- References
- 51
- Citations by year
- 2026: 160 · 2025: 231 · 2024: 316 · 2023: 373 · 2022: 409 · 2021: 355
- FWCI
- 178.84
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- New England Journal of Medicine (publishedVersion, other-oa)
- PubMed (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion, other-oa)
- Institutional Research Information System (Università degli Studi di Brescia) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Funders
- Sanofi
- Lexicon Pharmaceuticals
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Keywords
- sotagliflozin, SGLT2 inhibitors, type 2 diabetes, worsening heart failure, acute decompensated heart failure, heart failure hospitalization, cardiovascular mortality, diarrhea, hypoglycemia, drug safety, DAPA-HF
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Aged, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Glycosides, Heart Failure, Hospitalization, Humans, Hypotension, Male, Middle Aged, Sodium-Glucose Transporter 1, Acute Kidney Injury
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
